Fenwick represented Graybug Vision (NASDAQ: GRAY) in its definitive merger agreement with CalciMedica, a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for life-threatening inflammatory diseases, to combine the companies in an all-stock transaction.
The combined company will focus on further developing CalciMedica’s lead product candidate Auxora™, a proprietary, intravenous-formulated, small molecule calcium-release activated calcium (CRAC) channel inhibitor, to treat life-threatening inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated pancreatitis (AAP), acute kidney injury (AKI) and acute hypoxemic respiratory failure (AHRF), for which there are no currently approved therapies. More information can be obtained from Graybug Vision’s announcement.
Fenwick has served as counsel to Graybug Vision for several years, led by corporate partner Effie Toshav. Fenwick represented Graybug Vision in its $90 million IPO in September 2020.
The Fenwick transaction team for this transaction included corporate partners David Michaels, Robert Freedman and Julia Forbess, counsel Jeremy Delman and associates Christopher Sun, Stan Yao, Riddhi Adhikari, Luke Finn, Christina Scully, Meg Moloney and Syeda Nawroj; technology transactions partner Jake Handy and associates Pinar Bailey, Kehl Sink and Catherine Kim; executive compensation and employee benefits partner Liz Gartland and associate Liza Morgan; privacy and cybersecurity counsel Helen Christakos and associates Samantha Ong and Alyona Eidinger; healthcare regulatory partner Jennifer Yoo; and tax associate Mike Knobler.